Prediagnostic Plasma Pyridoxal 50-Phosphate
(Vitamin B6) Levels and Invasive Breast Carcinoma Risk:
The Multiethnic Cohort
Galina Lurie1, Lynne R. Wilkens1, Yurii B. Shvetsov1, Nicholas J. Ollberding2, Adrian A. Franke1,
Brian E. Henderson3, Laurence N. Kolonel1, and Marc T. Goodman1
Background: Evidence from experimental and epidemiologic studies suggests that vitamin B6 may reduce
the risk of breast cancer.
Methods: We examined the association of prediagnostic plasma concentrations of pyridoxal-50-phosphate
(PLP), an active form of vitamin B6, with postmenopausal breast cancer risk in a case–control study nested in
the multiethnic cohort in Hawaii and Southern California, including 706 cases and 706 controls matched on
date of birth, ethnicity, study site, date of blood draw, time of blood draw, hours of fasting before blood draw,
and use of menopausal hormones. OR and 95% confidence intervals (CI) were calculated using conditional
logistic regression models.
Results: Women with plasma PLP concentrations in the highest quartile had a 30% reduced risk of invasive
breast cancer (CI: 0.50–0.98) as compared with the women in the lowest PLP quartile (P for trend ¼ 0.02). The
association seemed to be limited in cases with hormone receptor-positive tumors (P for heterogeneity ¼ 0.04);
before cancer diagnosis (OR ¼ 0.69; CI: 0.48–0.99; P for trend ¼ 0.03).
Conclusions: These data suggest that higher circulating levels of vitamin B6 are associated with a reduced
risk of invasive postmenopausal breast cancer.
vitamin B6 in the prevention of postmenopausal breast cancer. Additional studies are needed to further
investigate potential heterogeneity of the vitamin B6 association with breast cancer risk by tumor hormone
receptor status. Cancer Epidemiol Biomarkers Prev; 21(11); 1942–8. ?2012 AACR.
Identification of molecular mechanisms underlying
breast carcinogenesis is fundamental to the prevention
of breast cancer, the most common malignancy among
women (1). Although, many of the accepted breast cancer
risk factors, such as age at menarche, parity, age at first
modify, diet is a potentially modifiable factor. However,
besides alcohol intake, no association of diet with post-
menopausal breast cancer risk has been established (2).
Pyridoxal 50-phosphate (PLP), the active form of vita-
reactions (4). Vitamin B6 is involved in one-carbon
metabolism, a sequence of biochemical processes that
enrich the cellular supply of methyl groups for DNA
synthesis, repair, and methylation (5). Apart from its role
as a coenzyme, vitamin B6 might affect carcinogenesis
directly through inhibition of cell proliferation, oxidative
stress, angiogenesis, and enhanced immune function
(reviewed in ref. 6).
Results from studies of the association of dietary vita-
breast cancer risk are inconsistent. A randomized trial of
significantly reduced breast cancer risk among women in
women (21). Weinvestigated prediagnostic plasma levels
of PLP in relation to invasive breast cancer risk among
postmenopausal women in the multiethnic cohort (MEC)
Materials and Methods
Study design and population
This case–control study was nested within the bio-
specimen subcohort of the MEC, a large prospective
Hawaii;2Department of Health Studies, University of Chicago, Chicago,
University of Southern California, Los Angeles, California
1University of Hawaii Cancer Center, Honolulu,
Corresponding Author: Galina Lurie, Cancer Research Center of Hawaii,
1236 Lauhala Street, Room 502E, Honolulu, HI 96813. Phone: 808-564-
5981; Fax: 808-586-2982; E-mail: firstname.lastname@example.org
?2012 American Association for Cancer Research.
Cancer Epidemiol Biomarkers Prev; 21(11) November 2012
Matsubara K, Komatsu S, Oka T, Kato N. Vitamin B6-mediated
suppression of colon tumorigenesis, cell proliferation, and angiogen-
esis (review). J Nutr Biochem 2003;14:246–50.
Sellers TA, Kushi LH, Cerhan JR, Vierkant RA, Gapstur SM, Vachon
CM, et al. Dietary folate intake, alcohol, and risk of breast cancer in a
prospective study of postmenopausal women. Epidemiology 2001;
Levi F, Pasche C, Lucchini F, La Vecchia C. Dietary intake of selected
micronutrients and breast-cancer risk. Int J Cancer 2001;91:260–3.
Chen J, Gammon MD, Chan W, Palomeque C, Wetmur JG, Kabat GC,
et al. One-carbon metabolism, MTHFR polymorphisms, and risk of
breast cancer. Cancer Res 2005;65:1606–14.
10. Lajous M, Lazcano-Ponce E, Hernandez-Avila M, Willett W, Romieu I.
Folate, vitamin B(6), and vitamin B(12) intake and the risk of breast
cancer among Mexican women. Cancer Epidemiol Biomarkers Prev
11. Chou YC, Lee MS, Wu MH, Shih HL, Yang T, Yu CP, et al. Plasma
homocysteine as a metabolic risk factor for breast cancer: findings
from a case–control study in Taiwan. Breast Cancer Res Treat 2007;
carbon metabolism and risk of breast cancer among premenopausal
women. Cancer Epidemiol Biomarkers Prev 2007;16:2787–90.
13. Ma E, Iwasaki M, Junko I, Hamada GS, Nishimoto IN, Carvalho SM,
et al. Dietary intake of folate, vitamin B6, and vitamin B12, genetic
polymorphism of related enzymes, and risk of breast cancer: a case–
control study in Brazilian women. BMC Cancer 2009;9:122.
14. Maruti SS, Ulrich CM, White E. Folate and one-carbon metabolism
nutrients from supplements and diet in relation to breast cancer risk.
Am J Clin Nutr 2009;89:624–33.
carbon metabolism-related nutrients and risk of postmenopausal
breast cancer in the Cancer Prevention Study II Nutrition Cohort. Am
J Clin Nutr 2010;91:1708–15.
16. Shrubsole MJ, Shu XO, Li HL, Cai H, Yang G, Gao YT, et al. Dietary B
vitaminand methionine intakes andbreastcancerriskamong Chinese
women. Am J Epidemiol 2011;173:1171–82.
17. Zhang CX, Ho SC, Chen YM, Lin FY, Fu JH, Cheng SZ. Dietary folate,
vitamin B6, vitamin B12 and methionine intake and the risk of breast
cancer by oestrogen and progesterone receptor status. Br J Nutr
J. A prospective study on folate, B12, and pyridoxal 50-phosphate (B6)
19. Zhang SM, Willett WC, Selhub J, Hunter DJ, Giovannucci EL, Holmes
MD, et al. Plasma folate, vitamin B6, vitamin B12, homocysteine, and
risk of breast cancer. J Natl Cancer Inst 2003;95:373–80.
20. Lin J, Lee IM, Cook NR, Selhub J, Manson JE, Buring JE, et al. Plasma
folate, vitamin B-6, vitamin B-12, and risk of breast cancer in women.
Am J Clin Nutr 2008;87:734–43.
21. Zhang SM, Cook NR, Albert CM, Gaziano JM, Buring JE, Manson JE.
Effect of combined folic acid, vitamin B6, and vitamin B12 on cancer
risk in women: a randomized trial. JAMA 2008;300:2012–21.
22. Kolonel LN, Henderson BE, Hankin JH, Nomura AM, Wilkens LR, Pike
MC, et al. A multiethnic cohort in Hawaii and Los Angeles: baseline
characteristics. Am J Epidemiol 2000;151:346–57.
23. Rybak ME, Pfeiffer CM. Clinical analysis of vitamin B(6): determination
of pyridoxal 50-phosphate and 4-pyridoxic acid in human serum by
reversed-phase high-performance liquid chromatography with chlo-
rite postcolumn derivatization. Anal Biochem 2004;333:336–44.
24. Therneau TM, Grambsch PM. Modeling survival data: extending the
Cox model. New York: Springer; 2000.
25. Zhu K, Davidson NE, Hunter S, Yang X, Payne-Wilks K, Roland CL,
et al. Methyl-group dietary intake and risk of breast cancer among
African-American women: a case–control study by methylation status
of the estrogen receptor alpha genes. Cancer Causes Control
26. Jones PA, Buckley JD. The role of DNA methylation in cancer. Adv
Cancer Res 1990;54:1–23.
27. Lapidus RG, Ferguson AT, Ottaviano YL, Parl FF, Smith HS, Weitz-
man SA, et al. Methylation of estrogen and progesterone receptor
gene 50CpG islands correlates with lack of estrogen and proges-
terone receptor gene expression in breast tumors. Clin Cancer Res
28. Piva R, Rimondi AP, Hanau S, Maestri I, Alvisi A, Kumar VL, et al.
Different methylation of oestrogen receptor DNA in human breast
carcinomas with and without oestrogen receptor. Br J Cancer 1990;
B16 melanoma growth by vitamin B6. Nutr Cancer 1985;7:43–52.
31. Shultz TD, Santamaria AG, Gridley DS, Stickney DR, Slater JM. Effect
of pyridoxine and pyridoxal on the in vitro growth of human malignant
melanoma. Anticancer Res 1988;8:1313–8.
32. Molina A, Oka T, Munoz SM, Chikamori-Aoyama M, Kuwahata M,
Natori Y. Vitamin B6 suppresses growth and expression of albumin
gene in a human hepatoma cell line HepG2. Nutr Cancer 1997;28:
33. Komatsu SI, Watanabe H, Oka T, Tsuge H, Nii H, Kato N. Vitamin B-6-
supplemented diets compared with a low vitamin B-6 diet suppress
azoxymethane-induced colon tumorigenesis in mice by reducing cell
proliferation. J Nutr 2001;131:2204–7.
34. Davis BA, Cowing BE. Pyridoxal supplementation reduces cell prolif-
eration and DNA synthesis in estrogen-dependent and -independent
mammary carcinoma cell lines. Nutr Cancer 2000;38:281–6.
35. Shimada D, Fukuda A, Kanouchi H, Matsumoto M, Oka T. Vitamin B6
suppresses growth of the feline mammary tumor cell line FRM. Biosci
Biotechnol Biochem 2006;70:1038–40.
36. Shimada D, Fukuda A, Kawaguchi H, Kato N, Yoshida H, Kanouchi H,
et al. Effect of high dose of pyridoxine on mammary tumorigenesis.
Nutr Cancer 2005;53:202–7.
37. Cidlowski JA, Thanassi JW. Pyridoxal phosphate: a possible cofactor
in steroid hormone action. J Steroid Biochem 1981;15:11–6.
38. Allgood VE, Cidlowski JA. Vitamin B6 modulates transcriptional acti-
vation by multiple members of the steroid hormone receptor super-
family. J Biol Chem 1992;267:3819–24.
39. Oka T. Modulation of gene expression by vitamin B6. Nutr Res Rev
40. Friso S, Jacques PF, Wilson PW, Rosenberg IH, Selhub J. Low
marker C-reactive protein independently of plasma homocysteine
levels. Circulation 2001;103:2788–91.
41. Morris MS, Sakakeeny L, Jacques PF, Picciano MF, Selhub J. Vitamin
B-6 intake is inversely related to, and the requirement is affected by,
inflammation status. J Nutr 2010;140:103–10.
42. Jain SK, Lim G. Pyridoxine and pyridoxamine inhibits superoxide
radicals and prevents lipid peroxidation, protein glycosylation, and
(Naþþ Kþ)-ATPase activity reduction in high glucose-treated human
erythrocytes. Free Radic Biol Med 2001;30:232–7.
Lurie et al.
Cancer Epidemiol Biomarkers Prev; 21(11) November 2012Cancer Epidemiology, Biomarkers & Prevention